\n| Subject<\/td>\n | \nThe 2022 Annual Shareholders' Meeting passes\r\nrelease the prohibition on directors from participation\r\nin competition businesses.<\/pre>\n<\/td>\n<\/tr>\n\n| Date of events<\/td>\n | 2022\/06\/21<\/td>\n | To which item it meets<\/td>\n | paragraph 21<\/td>\n<\/tr>\n | \n| Statement<\/td>\n | \n1.Date of the shareholders meeting resolution:2022\/06\/21\r\n2.Name and title of the director with permission to \r\n engage in competitive conduct:\r\n Director:Fu Hui-Tung\r\n Director:Chang Ming-Cheng\r\n Director:Hsieh Yen-Sheng\r\n Director:Excelsior Group Holdings Co., Ltd. \r\n Representative:Chen Tun-Ling\r\n Director:Excelsior Group Holdings Co., Ltd. \r\n Representative:Chang Hsien-Cheng\r\n Director:Fu Jo-Hsuan\r\n Independent director:Chang Wu-I\r\n Independent director:Kuo Yu-Chia\r\n Independent director:Jhan Cian-Long\r\n3.Items of competitive conduct in which the director \r\n is permitted to engage:\r\n Concurrently serve as a director with the same or \r\n similar business scope as the Company.\r\n4.Period of permission to engage in the competitive \r\n conduct: A director's term of office\r\n5.Circumstances of the resolution (please describe the \r\n results of voting in accordance with Article 209 of \r\n the Company Act): \r\n The resolution was adopted by a majority of the \r\n shareholders presented at the general meeting who\r\n represented two-thirds or more of the total number\r\n of shares represented by the attending shareholders.\r\n6.If the permitted competitive conduct belongs to the \r\n operator of a mainland China area enterprise, the \r\n name and title of the directors\r\n (if it is not the operator of a Mainland-area \r\n enterprise,please enter \u201cN\/A\u201d below):\r\n Director:Fu Hui-Tung\r\n Director:Fu Jo-Hsuan\r\n7.Company name of the mainland China area enterprise \r\n and the director's position in the enterprise:\r\n Director:Fu Hui-Tung\uff0cDirector of SinoExcelsior \r\n Investment Incorporation.\r\n Director:Fu Jo-Hsuan\uff0cDirector of SinoExcelsior \r\n Investment Incorporation.\r\n8.Address of the mainland China area enterprise:\r\n SinoExcelsior Investment Incorporation address:\r\n Room 301-2, No.1089, Kang Ning Lu, Shanghai Shi, China\r\n9.Operations of the mainland China area enterprise:\r\n enterprise management consulting, business information \r\n consulting,technical consulting and technical services \r\n in the professional field of medical technology (except\r\n for the development and application of human stem \r\n cells,gene diagnosis and treatment technology), and \r\n wholesale of cosmetics , import and export, beauty \r\n shop, barber shop (limited to branch operations).\r\n10.Impact on the company's finance and business:None.\r\n11.If the directors have invested in the mainland China\r\n area enterprise,the monetary amount of the investment\r\n and their shareholding ratio:None.\r\n12.Any other matters that need to be specified:None.<\/pre>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":" SEQ_NO \u00a03 Date of announcement 2022\/06\/21 Time of announcement 21:59:48 Subject The 2022 Annual Shareholders’ Meeting passes release the prohibition on directors from participation in competition businesses. Date of events 2022\/06\/21 To which item it meets paragraph 21 Statement 1.Date of the shareholders meeting resolution:2022\/06\/21 2.Name and title of the director with permission to …<\/p>\n The 2022 Annual Shareholders’ Meeting passes release the prohibition on directors from participation in competition businesses.<\/span> Read More »<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[72,102],"tags":[],"class_list":["post-6457","post","type-post","status-publish","format-standard","hentry","category-investors","category-material-information"],"_links":{"self":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts\/6457","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/comments?post=6457"}],"version-history":[{"count":8,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts\/6457\/revisions"}],"predecessor-version":[{"id":6478,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts\/6457\/revisions\/6478"}],"wp:attachment":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/media?parent=6457"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/categories?post=6457"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/tags?post=6457"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} | |